Tessa Jowell BRAIN MATRIX - Platform Study
BRAIN MATRIX
A British Feasibility Study of Molecular Stratification and Targeted Therapy to Optimize the Clinical Management of Patients With Glioma by Enhancing Clinical Outcomes, Reducing Avoidable Toxicity, Improving Management of Post-operative Residual & Recurrent Disease and Improving Survivorship
2 other identifiers
observational
1,000
1 country
14
Brief Summary
The main aim of the Tessa Jowell BRAIN MATRIX - Platform Study is to more precisely determine the exact type of tumour patients have by developing the essential infrastructure to provide rapid and accurate molecular diagnosis. A large network of clinical hubs across the United Kingdom, with expertise in managing patients with brain tumours, will be developed. Once established this infrastructure will facilitate the rapid introduction of clinical trials testing targeted therapies tailored to the genetic changes of an individual's tumour.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2020
Longer than P75 for all trials
14 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 14, 2020
CompletedFirst Posted
Study publicly available on registry
February 18, 2020
CompletedStudy Start
First participant enrolled
November 24, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
February 1, 2028
May 5, 2026
April 1, 2026
6.2 years
February 14, 2020
April 29, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
Time (from biopsy) to integrated histological-molecular diagnosis using standard-of-care NHS practice
This is defined as the difference (days) between date of biopsy and date of final local pathology report.
28 days
Time (from biopsy) to WGS report to the treating clinician using NHS Genomic Medicine Service
This is defined at the difference (days) between date of biopsy and date that a patient's Genomic Tumour Advisory Board (GTAB) report is produced.
28
Secondary Outcomes (15)
Time to completion of each node of tissue and imaging pathway
To be achieved within a timescale of up to 5 years
Tumour and biological sample(s) quality control status
To be achieved within a timescale of up to 5 years
Imaging quality control status
To be achieved within a timescale of up to 5 years
Inter-rater agreement of Response Assessment in Neuro-Oncology (RANO) assessments
To be achieved within a timescale of up to 5 years
Extent of surgical resection
To be achieved within a timescale of up to 5 years
- +10 more secondary outcomes
Interventions
Tessa Jowell BRAIN MATRIX centres in England can submit matched tissue and blood samples for Whole Genome Sequencing through the standard of care NHS Genomic Medicine Service pathway via their Genomic Laboratory Hub. For those from Devolved Nations, samples must go to the Oxford BRAIN MATRIX Laboratory who can facilitate the processing of samples through an alternative NHS GMS GLH or via the research pathway.
For patient's undergoing surgery fresh tissue will be collected from the initial surgery and frozen until shipment to the Oxford BRAIN MATRIX Lab. Matched blood sample for germline DNA will be taken post-Platform Study entry. For patients with progression with available tumour samples from previous tumour surgery, blood will be collected and sent to Oxford along with their tumour samples. Samples will be shipped together to Oxford for molecular analysis (Whole Genome Sequencing (WGS) and EPIC array). The BRAIN MATRIX neuropathology and genomics team will produce an integrated report (histology, WGS, Heidelberg Classifier) for each case in consultation with the local neuropathology team. Once data is available, a virtual MDT with the BRAIN MATRIX neuropathology, genomics team and local site will be held to ensure all relevant information is incorporated in the final BRAIN MATRIX diagnostic report. The resulting integrated histological-molecular report will be available to local sites
Eligibility Criteria
* Patients with a newly diagnosed suspected WHO Grade 2-4 glioma, (as evidenced radiologically) AND suitable for a diagnostic or therapeutic surgical procedure resulting in a frozen tumour sample matched to a blood sample. * Patients with progression with known WHO Grade 2-4 glioma (those with available frozen tumour will be prioritised for detailed genomic analysis).
You may qualify if:
- Newly diagnosed suspected WHO Grade 2-4 glioma, (as evidenced radiologically) AND suitable for a diagnostic or therapeutic surgical procedure resulting in a tumour sample matched to a blood sample.
- Patients with progression with known WHO Grade 2-4 glioma (those with available frozen tumour will be prioritised for detailed genomic analysis).
- Valid written informed consent for the study.
You may not qualify if:
- Primary spinal cord tumours
- Active treatment of other malignancy
- Contraindication to MRI
- Patients without standard of care imaging available
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Birminghamlead
- The Brain Tumour Charitycollaborator
- University of Oxfordcollaborator
- University of Edinburghcollaborator
- Genomics Englandcollaborator
Study Sites (14)
Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust
Birmingham, B15 2TH, United Kingdom
Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust
Cambridge, CB2 0QQ, United Kingdom
Velindre Cancer Centre, Velindre University NHS Trust
Cardiff, CF14 2TL, United Kingdom
NHS Lothian
Edinburgh, EH4 2XU, United Kingdom
Queen Elizabeth Unviersity Hospital, NHS Greater Glasgow and Clyde Health Board
Glasgow, G51 4TF, United Kingdom
St James's University Hospital, Leeds Teaching Hospitals NHS Trust
Leeds, LS9 7TF, United Kingdom
The Walton Centre, The Walton Centre NHS Foundation Trust
Liverpool, L9 7LJ, United Kingdom
King's College Hospital, King's College Hospital NHS Foundation Trust
London, SE5 9RS, United Kingdom
Charing Cross Hospital, Imperial College Healthcare NHS Trust
London, W6 8RF, United Kingdom
The Christie Hospital, The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust
Manchester, M6 8HD, United Kingdom
Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, NE7 7DN, United Kingdom
Queen's Medical Centre, Nottingham University Hospitals NHS Trust
Nottingham, NG7 2UH, United Kingdom
Churchill Hospital, Oxford University Hospitals NHS Foundation Trust
Oxford, OX3 9DU, United Kingdom
Related Publications (1)
Watts C, Savage J, Patel A, Mant R, Wykes V, Pohl U, Bulbeck H, Apps J, Sharpe R, Thompson G, Waldman AD, Ansorge O, Billingham L; TJBM Investigators. Protocol for the Tessa Jowell BRAIN MATRIX Platform Study. BMJ Open. 2022 Sep 8;12(9):e067123. doi: 10.1136/bmjopen-2022-067123.
PMID: 36378622BACKGROUND
Related Links
Biospecimen
* Fresh Frozen Tissue * Germline DNA * Liquid Biopsies
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Colin Watts
Unviersity of Birmingham
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 5 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 14, 2020
First Posted
February 18, 2020
Study Start
November 24, 2020
Primary Completion (Estimated)
February 1, 2027
Study Completion (Estimated)
February 1, 2028
Last Updated
May 5, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, ANALYTIC CODE
- Time Frame
- Data will be available within 1 year of study closure, if not before.
- Access Criteria
- See Plan Description above.
Scientifically sound proposals from appropriately qualified researchers will be considered for data sharing. Requests should be made by returning a Data Sharing Request Form to newbusiness@trials.bham.ac.uk; this captures the research requirements, statistical analysis plan, and intended publication schedule. Requests will be reviewed by the Cancer Research UK Clinical Trials Unit (CRCTU) Directors in discussion with the Chief Investigator (CI), Study Management Group (SMG) and independent Scientific Advisory Board (SAB). They will consider the scientific validity of the request, qualifications of the researchers, CI, SMG \& SAB views, consent arrangements, practicality of anonymizing the requested data \& contractual obligations. If supportive of the request, and where not already obtained, Sponsor consent for data transfer will be sought before notifying applicants of the outcome. It is anticipated that applicants will be notified within 3 months of receipt of the original request.